Late-breaking abstracts presented at ACR 2018 detail 3 promising options: a novel non-opioid analgesic and 2 disease-modifying OA drugs.
References1. Schnitzer TJ, Easton R, Pang S, et al. Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee [Abstract L20]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.2. McGuire D, Segal N, Metyas S, et al. Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness [Abstract L16]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.3. Yazici Y, McAlindon TE, Gibofsky A, et al. Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee [Abstract L03]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.This information is brought to you by Rheumatology Network and is not sponsored by, nor a part of, the American College of Rheumatology.
Three late-breaking abstracts presented at the American College of Rheumatology (ACR 2018) annual meeting in Chicago, IL, look at the latest treatment advances for osteoarthritis (OA). Schnitzer and colleagues at multiple centers in the US found that tanezumab provides significant pain relief and functional improvement in OA.1 McGuire and fellow researchers in California uncovered radiologic evidence that disease-modifying drugs for OA increase cartilage thickness.2 Finally, Yazici and associates at multiple centers in the US found the investigational disease-modifying OA drug SM04690 significantly improved pain and function in patients with OA.3 Scroll through the slides for the details of the studies and the take-home points for physicians.
IA, intra-articular; KOOS, Knee Osteoarthritis Outcome Scores; OA, osteoarthritis; PF, patellofemoral; TF, tibiofemoral; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
OA, osteoarthritis; PTGA, Patient Global Assessment; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.